Business
Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA
Ainos and SIDSCO will cooperate to accelerate the development of new animal drugs based on Ainos' VELDONA® low-dose oral interferonUpcoming clinical study
About this update from Ainos, Inc.
[{"type":"text","content":"Ainos and SIDSCO will cooperate to accelerate the development of new animal drugs based on Ainos' VELDONA® low-dose oral interferonUpcoming clinical study will investigate VELDONA®'s safe use and efficacy for the treatment of feline chronic gingivostomatitis (FCGS) via oral mucosal administrationSAN DIEGO, CA / ACCESSWIRE / November 6, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\", or the \"Company\"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it had signed a Memorandum of Understanding (\"MoU\") with SIDSCO Biomedical Co., Ltd. (\"SIDSCO\").The MoU is an important step in Ainos' strategy to expand its product line into the global pet care market. Under the agreement, Ainos and SIDSCO (collectively, the \"Parties\") will jointly explore the feasibility of VELDONA®/Cytoprotein contract clinical trials. Ainos intends to conduct animal clinical trials for veterinary investigational medicines in conjunction with SIDSCO, and will provide the technical knowledge, funding, and assistance required for the project.Ainos' low-dose oral interferon alpha (\"IFNα\") formulation, VELDONA®, is a human interferon first approved for sale by the Texas Department of Health in 1985 for the treatment of cats with feline leukemia and dogs with canine parvovirus. In 28 previous studies performed by Ainos, VELDONA® was found to exhibit systemic effects in mice, cats, dogs, ferrets, chickens, rats, guinea pigs, horses, calves/cows, and particularly pigs. VELDONA® has aided in boosting feed conversion efficiency and fighting deadly viral infections in these species, including canine parvovirus, equine herpesvirus, feline coronavirus, and others. These studies demonstrate that VELDONA® has a therapeutic or preventive effect via the oral mucosa. At the same time, VELDONA® modulates systemic and mucosal immunity without serious side effects.Previous studies have confirmed that feline interferon administered to the local oral mucosa can improve the clinical symptoms of pain in cats and the degree of inflammation in the affected area, and no serious adverse drug reactions occurred during the trial period. The experience of many veterinarians using over-the-counter medications has also shown that man...